Merck & Co., Inc. (NYSE:MRK) Q3 2023 Earnings Call Transcript

Dr. Dean Li: I think that’s a great question. I would just answer that. I think the TROP2 ADC data is important to look at, but I would also emphasize that the HER3 ADC program is reasonably advanced in that patient population. And so we will — we are interested in advancing both in getting the best medicines to the patients as quickly as we can. I do think more as a general statement that the role of biomarkers for some of these ADCs outside of EGFR will be important, relationship to tissue targeting, also in relationship more broadly for ADCs and other combinations. And so we will have to see how that field is moving, but essentially the way I think about ADCs is trying to bring chemotherapy in the precision medicine approach. And with that, we are going to have to find the right patient population, with the right biomarkers to give them the maximum benefit.

Rob Davis: Thank you, Mohit, and thank you all for your time and attention today. Please follow-up with Investor Relations if you have any additional questions and we look forward to being in touch soon. Thank you all very much.